GlassScriptPhysician profile
Sumbul Islam
NPI 1992898860
$3,523.39
in general payments reported to CMS, 2019-2025
30 companies · $667 in 2025
The $667 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $101 · 2021: $369 · 2022: $550 · 2023: $724 · 2024: $938 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,328.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $594.12 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $593.99 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $567.86 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $264.75 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $217.81 | 2023-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.33 | 2019-2024 | Jardiance |
| Amgen INC. | $172.61 | 2023-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $122.84 | 2022-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $120.23 | 2020-2022 | |
| Dexcom, INC. | $76.97 | 2023-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $69.37 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $61.90 | 2021-2022 | |
| Pfizer INC. | $56.30 | 2025 | |
| Abbott Laboratories | $55.29 | 2024-2025 | Eterna, Freestyle Libre 3, Proclaim |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.70 | 2025 | Caplyta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $47.91 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $39.25 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $29.23 | 2023 | Gemtesa |
| Genentech USA, INC. | $26.14 | 2021 | |
| Avanir Pharmaceuticals, INC. | $25.93 | 2021-2022 | |
| Corcept Therapeutics | $24.35 | 2025 | Korlym |
| Medline Industries LP | $21.87 | 2023 | |
| Medtronic, INC. | $17.64 | 2025 | Inceptiv |
| Evoke Pharma, INC. | $17.19 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.73 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.86 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.32 | 2021 | |
| Ironwood Pharmaceuticals, INC | $14.13 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.77 | 2025 | Xifaxan |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumbul Islam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.